Design, synthesis, molecular modelling, and in vitro evaluation of tricyclic coumarins against Trypanosoma cruzi

Chagas disease is caused by infection with the parasite protozoan Trypanosoma cruzi and affects about 8 million people in 21 countries in Latin America. The main form of treatment of this disease is still based on the use of two drugs, benznidazole and nifurtimox, which both present low cure rates i...

Full description

Saved in:
Bibliographic Details
Published in:Chemical biology & drug design 2019-03, Vol.93 (3), p.337-350
Main Authors: Coelho, Gleicekelly Silva, Andrade, Josimara Souza, Xavier, Viviane Flores, Sales Junior, Policarpo Ademar, Rodrigues de Araujo, Barbara Caroline, Fonseca, Kátia da Silva, Caetano, Melissa Soares, Murta, Silvane Maria Fonseca, Vieira, Paula Melo, Carneiro, Claudia Martins, Taylor, Jason Guy
Format: Article
Language:English
Subjects:
Binding Sites
Catalytic Domain
Chagas disease
coumarins
Coumarins - chemistry
Coumarins - metabolism
Coumarins - pharmacology
Drug Design
Humans
in silico
in vitro
isocoumarins
organocatalysis
Protozoan Proteins - antagonists & inhibitors
Protozoan Proteins - metabolism
Structure-Activity Relationship
Thermodynamics
tricyclic
Triose-Phosphate Isomerase - antagonists & inhibitors
Triose-Phosphate Isomerase - metabolism
triosephosphate isomerase
Trypanocidal Agents - chemical synthesis
Trypanocidal Agents - metabolism
Trypanocidal Agents - pharmacology
Trypanosoma cruzi
Trypanosoma cruzi - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chagas disease is caused by infection with the parasite protozoan Trypanosoma cruzi and affects about 8 million people in 21 countries in Latin America. The main form of treatment of this disease is still based on the use of two drugs, benznidazole and nifurtimox, which both present low cure rates in the chronic phase and often have serious side‐effects. Herein, we describe the synthesis of tricyclic coumarins that were obtained via NHC organocatalysis and evaluation of their trypanocidal activity. Molecular docking studies against trypanosomal enzyme triosephosphate isomerase (TIM) were carried out, as well as a theoretical study of the physicochemical parameters. The tricyclic coumarins were tested in vitro against the intracellular forms of Trypanosoma cruzi. Among the 18 compounds tested, 10 were more active than the reference drug benznidazole. The trypanocidal activity of the lead compound was rationalized by molecular docking study which suggested the strong interaction with the enzyme TIM by T. cruzi and therefore indicating a possible mode of action. Furthermore, the selectivity index of eight tricyclic coumarins with high anti‐T. cruzi activity was above 50 and thus showing that these lead compounds are viable candidates for further in vivo assays. Chagas disease is caused by infection with the parasite protozoan Trypanosoma cruzi and affects about 8 million people. We describe the synthesis of tricyclic coumarins that were obtained via NHC organocatalysis and evaluation of their trypanocidal activity. Molecular docking studies against trypanosomal enzyme triosephosphate isomerase were carried out, and 10 compounds were found to be more active than the reference drug benznidazole.
ISSN:1747-0277
1747-0285
DOI:10.1111/cbdd.13420